Security key
46489V302
Perspective Therapeutics, Inc. - Common Stock, par value $0.001 per share (CATX)
CUSIP: 46489V302
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 38,531,736
- Total 13F value
- $384,149,816
- Share change
- +38,503,012
- SEC-reported price per share
- $9.97
- Number of holders
- 102
- Value change
- +$383,863,185
- Number of buys
- 100
- Shares outstanding
- 113,811,233
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
102
Top holders
10
CATX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Perspective Therapeutics, Inc. SEC filings
Perspective Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 46489V302
Recent filing periods:
Ownership snapshot
Top reported holders of CATX - Perspective Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lantheus Alpha Therapy, LLC
Disclosed value leader
Lantheus Alpha Therapy, LLC
Comparable rows
0/6
Latest evidence
06 Mar 2024
3/4/5
Highest disclosed value: $110,934,724
6 rows are not safely comparable across share classes.
Quick read
Lantheus Alpha Therapy, LLC has the largest disclosed position value at $110.93M.
0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lantheus Alpha Therapy, LLC's linked filing trail.
Disclosed position value
Top 1
Lantheus Alpha Therapy, LLC
$110.93M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$110,934,724
116,773,394 shares
|
— | 06 Mar 2024 |
| Jennifer Streeter |
3/4/5
COO & VP of HR
|
—
class O/S missing
|
—
1,722,500 shares
|
— | 12 Jun 2023 |
| William Cavanagh |
3/4/5
Chief R&D Officer
|
—
class O/S missing
|
—
1,493,846 shares
|
— | 21 Jul 2022 |
| Michael W. McCormick |
3/4/5
Director
|
—
class O/S missing
|
—
1,124,615 shares
|
— | 21 Feb 2023 |
| Philip J. Vitale |
3/4/5
Director
|
—
class O/S missing
|
—
425,000 shares
|
— | 21 Jul 2022 |
| Alan Hoffmann |
3/4/5
Director
|
—
class O/S missing
|
—
424,615 shares
|
— | 21 Jul 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
102
Shares
38,531,736
Rows available
102
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q4 2025 Across Filers
Q4 2025 holders
114
Q2 2024 holders
102
Holder diff
-12
| Investor | Q4 2025 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend